The Optimization Pathogenetic Therapy of a Stroke

Authors

  • E.M. Mirdjuraev Tashkent Institute of Postgraduate Medical Education, Uzbekistan
  • M.A. Bakhadirova Tashkent Institute of Postgraduate Medical Education, Uzbekistan
  • N.O. Ergasheva Tashkent Institute of Postgraduate Medical Education, Uzbekistan

DOI:

https://doi.org/10.61788/njn.v2i16.04

Keywords:

ischemic stroke, treatment, drug PK-Mertz

Abstract

There were conduced researches of efficiency and safety of application of the antagonist of glutamate NMDA-receptors at patients in the acute period of a stroke. As a medical therapy has been chosen PK-Mertz. Against the background of treatment in the main group it was noted reduction of neurologic deficiency on a scale NIHSS for 39.1% (р<0.005). At the same time the good effect was observed at patients with a slight stroke (assessment on NIHSS<7). It doesn’t depend on age and subtype of ischemic stroke.

References

Болезни нервной системы: Руководство для врачей: в 2-х т. – Т1, Под Ред. Яхно Н.Н., Штульмана Д.Р – 3-е издание, перераб и доп. – М.: Медицина, 2003.-744с.

Гусев Е.И., Скворцова В.И., Платонова И.А, Терапия ишемического инсульта // Consilium Medicum (спец. выпуск).2003;18-25.

Инсульт. Принципы диагностики, лечения и профилактики: краткое руководство для врачей. Под ред. Н.В.Верещагина, М. А. Пирадова, З.А.Суслиной. М., 2002. стр-206.

Скворцова В.И., Механизмы повреждающего действия церебральной ишемии и новые терапевтические стратегии // Журнал неврологии и психиатрии 2003;9:20-25.

Суслина З.А. Лечение ишемического инсульта. Лечение нервных болезней 2000;1:1:3-7.

Blanpied T.A., Clarke R.J., Johnson J.W. Amantadine inhibitis NMDA-receptors By accelerating channel closure during channel block // J neuro sci 2005;25:3312-3322.

Culmsee C., Junker V., Kremers W. et al. Combination therapy in ischemic stroke: synergistic neuroprotiye effects of memantine and clenbuterol // Stroke 2004;32:1197-1202.

Davis S.M., Lees Albers G.W. et al. Selfotel in Acute Ischemic Stroke: Possible Neurotoxic Effects of an NMDA Antagonist // Stroke 2000;31:347-354.

Evans A., Harraf F., Donaldson N., Lalit K. Randomized Controlled Study of Stroke Unit Care Versus Stroke Team in Different Stroke Subtypes // Stroke 2002;33:449-455.

Fisher M., Davalos A., Rogalewski et al. Toward a Multimodal Neuroprotective Treatment of Stroke // Stroke 2006;37:1129-1136.

Keith W. Muir Heterogeneity of Stroke Pathophysiology and Neuroprotictive Clinical Trial Design // Stroke 2002;33:1545-1550.

Lees, Dyker A.G., Sharma A. et al. Tolerability of the Low-Affinity, Use Dependent NMDA Antagonist AR-R15896Ar in Stroke Patients : A Dose-Ranging Study // Stroke 2001;32:466-472.

Downloads

Published

31.12.2016

How to Cite

Mirdjuraev, E., Bakhadirova, M., & Ergasheva, N. (2016). The Optimization Pathogenetic Therapy of a Stroke. National Journal of Neurology, 27–29. https://doi.org/10.61788/njn.v2i16.04

Issue

2016: No.2 (10)

Section

Original Articles

License

Copyright (c) 2026 National Association of Neurologists

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.